Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
2.
ImmunoHorizons ; 6(12):851-863, 2022.
Article in English | MEDLINE | ID: covidwho-2201353

ABSTRACT

The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease (COVID-19) has led to a pandemic of unprecedented scale. An intriguing feature of the infection is the minimal disease in most children, a demographic at higher risk for other respiratory viral diseases. To investigate age-dependent effects of SARS-CoV-2 pathogenesis, we inoculated two rhesus macaque monkey dam-infant pairs with SARS-CoV-2 and conducted virological and transcriptomic analyses of the respiratory tract and evaluated systemic cytokine and Ab responses. Viral RNA levels in all sampled mucosal secretions were comparable across dam-infant pairs in the respiratory tract. Despite comparable viral loads, adult macaques showed higher IL-6 in serum at day 1 postinfection whereas CXCL10 was induced in all animals. Both groups mounted neutralizing Ab responses, with infants showing a more rapid induction at day 7. Transcriptome analysis of tracheal airway cells isolated at day 14 postinfection revealed significant upregulation of multiple IFN-stimulated genes in infants compared with adults. In contrast, a profibrotic transcriptomic signature with genes associated with cilia structure and function, extracellular matrix composition and metabolism, coagulation, angiogenesis, and hypoxia was induced in adults compared with infants. Our study in rhesus macaque monkey dam-infant pairs suggests age-dependent differential airway responses to SARS-CoV-2 infection and describes a model that can be used to investigate SARS-CoV-2 pathogenesis between infants and adults.

3.
Innov Aging ; 6(Suppl 1):554, 2022.
Article in English | PubMed Central | ID: covidwho-2188990

ABSTRACT

The estimated 5 million persons living with dementia in the United States have been greatly impacted by the medical and psychosocial impacts of the COVID-19 pandemic, respite program closures, social isolation, and Veterans seen within the Veterans Health Administration system are particularly vulnerable. Telemedicine provides needed specialty dementia care to these patients with complex needs in their homes, and its uptake has increased during the pandemic. This qualitative, observational study explored informal caregivers' perceptions of tele-dementia care for Veterans seen at 2 sites, Palo Alto and Cleveland, via semi-structured interviews. Twenty-five caregivers (Mean age = 67y, SD=12y, 88% women) were interviewed over telephone following a tele-dementia visit. Themes that emerged from the interviews were that tele-dementia visits: (1) saved caregivers 2.6h±1.5h (Range: 0.5 to 6h) of travel time, (2) required limited preparation compared to in-person visits, (3) mitigated COVID-19 risk and avoided needs for masking and social distancing, (4) avoided behavioral challenges during appointments, and (5) allowed participation from home with minimal disruption of routine. Caregivers described significant physical challenges that made leaving the home for appointments difficult including balance issues, incontinence, and difficulties getting into vehicle. Caregivers plan to continue using tele-dementia services beyond the pandemic due to the convenience. Taken together, these findings indicate that caregivers find tele-dementia care convenient, comfortable, helpful, and timesaving and highly satisfactory. A combination of both in-person and virtual visits would be an ideal future state. This study illustrates how caregivers experience virtual visits for dementia care and will shape future intervention design.

4.
Journal of Sport & Tourism ; 26(4):335-362, 2022.
Article in English | CAB Abstracts | ID: covidwho-2151497

ABSTRACT

Advancements in experiential media (EM) technologies, particularly virtual reality (VR), a subset of EM, can transform the ways public relations (PR) professions tell stories about a brand, organization, or mega-events. In the context of sports, PR content productions utilize various qualities of EM to offer immersive at-home, arena-like experiences for sports spectators. However, considering the novelty of such EM tools, limited studies have focused on how and the extent to which PR and sports journalistic content productions use VR technologies. In this qualitative content analysis, we examine how and the extent to which VR is utilized in pre-game YouTube VR contents produced for the FIFA World Cups 2018 and 2022. We analyzed YouTube VR contents produced by Russia Today (RT) in the buildup to 'Russia 2018' hosted by Russia, in comparison with pre-game YouTube VR contents produced by the Road To 2022, in view of the upcoming 'Qatar 2022'. Through qualitative analyses, we identified four broad thematic categories: stadium design, technology, facilities, and locality, as well as many sub-themes through observations and memos from all the seventeen YouTube VR content productions considered for the study. This study adds to the theoretical discussions on the role VR plays in sports journalism and sports PR and provides practical recommendations on the use of virtual reality during the COVID-19 pandemic.

5.
Sci Transl Med ; : eadd6383, 2022.
Article in English | PubMed | ID: covidwho-2137395

ABSTRACT

The U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3 M-052, a synthetic toll-like receptor (TLR) 7/8 agonist, in a squalene emulsion (Protein+3 M-052-SE) was safe and immunogenic in infant rhesus macaques. Here, we demonstrate that broadly neutralizing and spike-binding antibodies against variants of concern (VOC), as well as T cell responses, persisted for 12 months. At one year, corresponding to human toddler age, we challenged vaccinated rhesus macaques and age-matched non-vaccinated controls intranasally and intratracheally with a high-dose of heterologous SARS-CoV-2 B.1.617.2 (Delta). Seven of eight control rhesus macaques exhibited severe interstitial pneumonia and high virus replication in the upper and lower respiratory tract. In contrast, vaccinated rhesus macaques had faster viral clearance with mild to no pneumonia. Neutralizing and binding antibody responses to the B.1.617.2 variant at the day of challenge correlated with lung pathology and reduced virus replication. Overall, the Protein+3 M-052-SE vaccine provided superior protection to the mRNA-LNP vaccine, emphasizing opportunities for optimization of current vaccine platforms. Notably, the observed efficacy of both vaccines one year after vaccination supports the implementation of an early life SARS-CoV-2 vaccine.

7.
Text (Australia) ; 26(1), 2022.
Article in English | Scopus | ID: covidwho-2081624

ABSTRACT

Since 2014, the Writers Immersion and Cultural Exchange (WrICE) program has sought to invite genuine trans-cultural encounters and dialogue among peer creative writers from different nations, cultural backgrounds, interests and life experiences across Asia and Australia. These have been enacted through in-person collaborative residencies, designed and staged based on a set of five compositional principles. In 2020, these principles were challenged, tested and elaborated in new ways through a new WrICE residency conducted entirely online: a move made necessary by the COVID-19 pandemic and its conditions of physical separation. Our findings from this digital residency experience offer insights into future directions for approaching transnational collaboration and dialogue among writers, artists, scholars, activists and others in a more constrained world, during and after the pandemic. Biographical note: Sreedhevi Iyer is a Lecturer in Creative Writing at RMIT University. She is the author of two books, Jungle Without Water (2017) and The Tiniest House of Time (2020). Her forthcoming monograph focuses on how authors perform authenticity across multiple communicative contexts. Her creative works have been published in several countries. Alvin Pang is Adjunct Professor at RMIT University. A poet, writer, editor, scholar and translator, his creative practice spans over two decades of literary activity in Singapore and elsewhere. With his writing translated into more than twenty languages worldwide, his latest titles include What Happened: Poems 1997-2017 (Math Paper Press, 2017) and Uninterrupted Time (Recent Work Press, 2019). David Carlin is Professor of Creative Writing and co-founder of both WrICE and the non/fictionLab at RMIT University. His work includes four books of essayist nonfiction, including The After-Normal: Brief, Alphabetical Essays on a Changing Planet (2019, with Nicole Walker), 100 Atmospheres: Studies in Scale and Wonder (2019, with MECO Network), and three co-edited anthologies. David is Co-President of NonfictioNOW. © 2022, Australasian Association of Writing Programs. All rights reserved.

8.
Futuristic Trends for Sustainable Development and Sustainable Ecosystems ; : 104-125, 2022.
Article in English | Scopus | ID: covidwho-2024506

ABSTRACT

COVID-19 has various symptoms, and they are cold, cough, mild or high fever, and breathing problems for severe cases. In addition, it is in talk that diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular, asthma, and many diseases invite the virus. Machine learning and data analysis are considered best for predicting approaches for finding various aspects of the effect of the virus. In this chapter, the authors deal with symptoms that have been recorded in the dataset and try to find which pre-defined symptoms are considered effective or responsible in positive case of infection by coronavirus. The dataset has been taken from Kaggle. As the dataset is categorical in nature, the authors use correlation and logistic regression analysis to find the symptoms that prevail in the patient and have caused the infection in them. This is also about dimensionality reduction and feature selection where they are reducing the available features based on regression. © 2022, IGI Global.

9.
IISE Annual Conference and Expo 2022 ; 2022.
Article in English | Scopus | ID: covidwho-2012915

ABSTRACT

The semiconductor industry has faced supply chain manufacturing shortages that ultimately led to a worldwide chip shortage during the COVID-19 pandemic. These chip manufacturers use sophisticated and advanced manufacturing machinery in their fabs to manufacture chips. As experienced during the pandemic, manufacturing unavailability is often due to the lack of critical manufacturing-related spare parts. This thesis evaluates the effectiveness of machine learning algorithms to identify significant factors contributing to manufacturing part outages (i.e., zero-bin) to keep manufacturing equipment running at total capacity within the organization. We propose clustering methods to segment the data and use logistic regression, logistic lasso regression, and kNN approaches to identify important factors for those parts that could go to zero-bin. Extant research applies classic inventory management strategies based on expenditure, criticality, or usage to manage their parts' inventory throughout the year. Instead, the proposed methods explore whether predefined, static inventory parameters can predict whether a spare part reaches zero bin. To demonstrate the viability of this approach, we present a case study using one year's worth of data from a leading chip manufacturing company. Based on the modeling approaches, a lasso-based logistic regression proved the best predictive model amongst the five clusters with lead-time, current quantity available, days on inventory (usage remained relevant), and the part's reorder point being the most significant parameters. © 2022 IISE Annual Conference and Expo 2022. All rights reserved.

10.
Journal of Clinical Oncology ; 40(16), 2022.
Article in English | EMBASE | ID: covidwho-2009550

ABSTRACT

Background: Disruptions to cancer care during the COVID-19 pandemic due to disease mitigation efforts, supply-chain issues, and fear of COVID-19 have all been reported, but study of their extent has been limited. The purpose of this study is to evaluate the extent and associations with patient reported disruptions to cancer treatment and other care during the COVID-19 pandemic using nationally representative data. Methods: This cross-sectional study uses data from the 2020 National Health Interview Survey (NHIS), an annual, cross-sectional survey of US adults. Adults who reported requiring current cancer treatment or other care related to their cancer in the second half of 2020 were included. Rates of patients with self-reported changes, delays, or cancellations to cancer treatment or other cancer-related care due to the COVID-19 pandemic were calculated and their associations with demographic and other variables were analyzed. All data were adjusted using sample weights and specific variables to account for stratification and other survey characteristics using the Stata svy command. Chi-square testing was used to compare proportions across variable groups. Univariable logistic regression analysis was utilized to assess variable associations with change, delay, or cancellations to cancer care during the COVID-19 pandemic. Multivariable logistic regression analysis was used to create a model adjusted for select demographic variables. Results: A sample-weighted 2,867,326 adults (n=574) reported requiring cancer treatment and/or other cancer care since the start of the COVID-19 pandemic. Of these, 189 (32.1%) reported any change, delay, or cancellation due to the pandemic. On univariable analysis, patients who were younger, female, had comorbidities, and uninsured were significantly more likely to report care disruptions. On adjusted analysis, younger age and female sex remained significant predictors. In a sample-weighted subset of 1,600,587 patients (n=331), 291 (87.9%) reported virtual appointment use. There was no association with disruptions across breast, prostate, lung, and colorectal cancer groups. Conclusions: Approximately 1/3 of patients experienced disruptions to cancer care during the COVID-19 pandemic. Patients with younger age or female sex were more likely to have disruptions in care, which may reflect risk stratification strategies in the early stages of the pandemic. The longitudinal impact of these disruptions on outcomes merits further study.

11.
2022 IEEE International Conference on Distributed Computing and Electrical Circuits and Electronics, ICDCECE 2022 ; 2022.
Article in English | Scopus | ID: covidwho-1932096

ABSTRACT

SARS-CoV-2, also known as the Coronavirus, is a disease belonging to the SARS-CoV family, first reported in December 2019 in Wuhan, China. It has since spread to several countries and has become a global threat. The issues of the Covid-19 pandemic are being tackled with the help of technological breakthroughs. Artificial Intelligence (AI) and Machine Learning (ML) play crucial roles in addressing this problem. Many organizations have been developing various devices to monitor the health parameters of a person from time to time. This work aims to study these parameter values and identify patterns within the data to predict whether a person is infected with Covid-19 or not. Different Classification algorithms such as Decision Tree, Random Forest, Support Vector Machine, Naive Bayes, and Logistic Regression are employed. The Random Forest showed the highest performance among the algorithms mentioned above, demonstrating 99.03% accuracy. This article also suggests Anti-Covid Strategies, such as Mask Detection and Social Distancing. A Mask Detection model is constructed utilizing Transfer Learning and existing Image Classification Networks, and the best one is VGG-19 which has obtained 99.31% test accuracy. © 2022 IEEE.

12.
Topics in Antiviral Medicine ; 30(1 SUPPL):75, 2022.
Article in English | EMBASE | ID: covidwho-1880788

ABSTRACT

Background: SARS-CoV-2 infection results in a spectrum of disease severity attributable to the magnitude of the underlying inflammatory response. Aged individuals with co-morbidities are most vulnerable and severely affected, but the mechanisms driving aberrant immune responses fueling SARS-CoV-2 immunopathology in this high-risk population are not fully elucidated. We hypothesized that asymptomatic CMV infection might exacerbate SARS-CoV-2 pathogenesis since its replication is both a cause and consequence of inflammation and appears to worsen oxygenation in critically ill patients (Limaye, JAMA, 2017). CMV-seropositivity was associated with increased hospitalization among people with SARS-CoV-2 infection (Shrock, Science, 2020). To begin to address this hypothesis, we utilized the rhesus macaque model of natural rhesus (Rh)CMV infection to investigate the extent to which SARS-CoV-2 induces CMV reactivation in the anatomic sites of SARS-CoV-2 pathology. Methods: To assess CMV reactivation, eight aged, type 2 diabetic RhCMV-seropositive rhesus macaques (sera anti-CMV IgG: 300-1400 ng/ml) were infected with high-dose SARS-CoV-2 (2.5x10 6 PFU) and monitored for 7 days prior to euthanasia. Samples from the respiratory tract, intestinal tract, and blood were collected to assess viral and inflammatory dynamics in distinct tissue compartments. Results: Following infection, SARS-CoV-2 replication was observed throughout the respiratory tract, which was associated with local and systemic inflammation and immune activation. Lung histopathological assessments revealed development of interstitial pneumonia with colocalization of SARS nucleocapsid protein within pneumocytes. qPCR assays targeting RhCMV gB showed CMV DNA within the caudal lung lobe (up to 103 CMV DNA copies/mg of tissue) in all animals at day 7, and the animal with the highest CMV DNA presented with the most profound clinical symptoms. Strikingly, CMV DNA copies strongly correlated with CD4 and CD8 T cell activation indices in blood and spleen (r = 0.96, p< 0.001). Additionally, we found RhCMV reactivation in the ileum, where high levels of ACE2 are reported. Conclusion: SARS-CoV-2 infection of RhCMV-seropositive macaques results in CMV reactivation in the anatomic sites where SARS-CoV-2 causes pathology. Future experimental studies should address whether CMV reactivation exacerbates SARS-CoV-2 pathogenesis.

13.
1st International Conference on Technologies for Smart Green Connected Society 2021, ICTSGS 2021 ; 107:17001-17007, 2022.
Article in English | Scopus | ID: covidwho-1874875

ABSTRACT

COVID - 19 pandemic has brought many problems after recovery. The problems ranges from body functions to all other small issues related to health. But the major impact of COVID - 19 has been on mental health resulting into suicidal tendencies in many patients. Due to lockdown in many parts of country, people have been in their home for a major part of time which has resulted into changes in their mental condition. Socializing has been minimal and going out to work also was hampered due to work from home. In January 2021, 41% adults have been reported with problems of mental fatigue. The efficiency has come down, the outcome of work has been to 80% - 85%, business has gone down because of less innovation and creativeness ability and other related problems. Yoga is giving an impetus to life for many, so to cope up with mental problems the various asanas is providing remedies which will be effective for the entire life. The asanas are being promoted by many yoga experts. The various recommended asanas will provide support to patients having mental problems which are very simple. The yoga guru send a message that if the asanas are done regularly and systematically to get relieved from many different ailment. If the recommended asanas are performed each day it will lead to a better life even if you are suffering from any long term ailment. In this article few postures (asana's) which can be performed at any time in the day but early morning will always be preferred (empty stomach) to get good result. All the asanas should be performed in presence of a trained person after due consultation with your physician. © The Electrochemical Society

14.
Blood ; 138(SUPPL 1):3525, 2021.
Article in English | EMBASE | ID: covidwho-1770434

ABSTRACT

Background - The WINDOW-1 regimen introduced first-line ibrutinib with rituximab (IR) followed by 4 cycles of R-HCVAD for younger mantle cell lymphoma (MCL) patients (pts) demonstrating 90% CR on IR alone and we aimed to improve the CR rate with the addition of venetoclax. We therefore investigated the efficacy and safety of IR and venetoclax (IRV) followed by risk-stratified observation or short course R-HCVAD/MTX-ARA-C as consolidation in previously untreated young patients with mantle cell lymphoma (MCL). Our aim was to use a triplet chemotherapy-free induction to reduce the toxicity, complications and minimize chemotherapy exposure in MCL pts. Methods - We enrolled 50 previously untreated pts in this single institution, single arm, phase II clinical trial - NCT03710772. Pts received IR induction (Part-1) for initial 4 cycles. Pts were restaged at cycle 4 and received IRV for up to eight cycles (Cycle 5 to Cycle 12) starting with ramp up venetoclax dosing in Cycle 5. All pts who achieved CR prior to cycle 12 continued to receive IRV for 4 cycles (maximum 12 cycles) and then moved to part 2. Pts were stratified into three disease risk groups: high, moderate and low risk categories from the baseline data for assignment to R-HCVAD/MTX-ARA-C as consolidation in part 2 (4 cycles, 2 cycles, or no chemotherapy for high, medium and low risk pts respectively). Briefly, low risk pts were those with Ki-67 ≤30%, largest tumor mass <3 cm, low MIPI score and no features of high risk disease (Ki-67 ≥50%, mutations in the TP53, NSD2 or in NOTCH genes, complex karyotype or del17p, MYC positive, or largest tumor diameter >5 cm or blastoid/pleomorphic histology or if they remain in PR after 12 cycles of part 1. Medium risk are pts which did not belong to low or high-risk category. Those who experienced progression on part 1 went to part 2 and get 4 cycles of part 2. Patient were taken off protocol but not off study, if they remained in PR after 4 cycles of chemotherapy, these patients were followed up for time to next treatment and progression free survival on subsequent therapies. After part 2 consolidation, all pts received 2 years of IRV maintenance. The primary objective was to assess CR rates after IRV induction. Adverse events were coded as per CTCAE version 4. Molecular studies are being performed. Results - Among the 50 pts, the median age was 57 years (range - 35-65). There were 20 pts in high-risk group, 20 pts in intermediate-risk group and 10 pts in low-risk group. High Ki-67 (≥30%) in 18/50 (36%) pts. Eighteen (36%) had high and intermediate risk simplified MIPI scores. Six (12%) pts had aggressive MCL (blastoid/pleomorphic). Among the 24 TP53 evaluable pts, eight pts (33%) had TP53 aberrations (mutated and/or TP53 deletion by FISH). Forty-eight pts received IRV. Best response to IRV was 96% and CR of 92%. After part 2, the best ORR remained unaltered, 96% (92% CR and 4% PR). The median number of cycles of triplet IRV to reach best response was 8 cycles (range 2-12). Fifteen pts (30%) did not receive part 2 chemotherapy, two pts (4%) received 1 cycle, 16 pts (32%) 2 cycles and 13 pts (26%) got 4 cycles of chemotherapy. With a median follow up of 24 months, the median PFS and OS were not reached (2 year 92% and 90% respectively). The median PFS and OS was not reached and not significantly different in pts with high and low Ki-67% or with/without TP53 aberrations or among pts with low, medium or high-risk categories. The median PFS and OS was inferior in blastoid/pleomorphic MCL pts compared to classic MCL pts (p=0.01 and 0.03 respectively). Thirteen pts (26%) came off study - 5 for adverse events, 3 for on study deaths, and 2 for patient choice, 2 patients lost to follow up and one for disease progression. Overall, 5 pts died (3 on trial and 2 pts died off study, one due to progressive disease and another due to COVID pneumonia). Grade 3-4 toxicities on part 1 were 10% myelosuppression and 10% each with fatigue, myalgia and rashes and 3% mucositis. One pt developed grade 3 atrial flutter on part 1. None had grade 3-4 bleeding/bruising. Conclusions - Chemotherapy-free induction with IRV induced durable and deep responses in young MCL pts in the frontline setting. WINDOW-2 approach suggests that pts with low risk MCL do not need chemotherapy but further follow up is warranted. This combined modality treatment approach significantly improves outcomes of young MCL pts across all risk groups. Detailed molecular analyses will be reported. (Figure Presented).

15.
Blood ; 138(SUPPL 1):133, 2021.
Article in English | EMBASE | ID: covidwho-1770356

ABSTRACT

Introduction: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of lymphomas associated with poor outcomes following anthracycline-based chemotherapy, even when consolidative autologous stem cell transplantation (ASCT) is used. CD30 expression is universal in anaplastic large cell lymphoma (ALCL) and is frequently expressed in other PTCL subtypes. Brentuximab vedotin (BV) is a CD30-directed antibody drug conjugate that prolongs progression-free survival (PFS) and overall survival (OS) when combined with cyclophosphamide, doxorubicin, and prednisone (CHP) as compared to CHOP chemotherapy (Horwitz, 2020). Although a majority of pts treated with BV-CHP remained in durable remission (5y PFS 51%), there is room for improvement. Based on retrospective studies that demonstrated improved outcomes in younger pts, the addition of etoposide to CHOP (CHOEP) is commonly used as initial therapy for PTCL. We performed a multicenter phase 2 trial to evaluate the safety and efficacy of adding etoposide to BV-CHP (CHEP-BV) followed by BV consolidation in pts with newly diagnosed CD30-expressing PTCL. Methods: Adults with newly diagnosed CD30+ (≥ 1% of tumor cells by local pathology) PTCL were eligible, including pts with ALK+ ALCL and IPI score ≥ 2, ALK-negative ALCL, PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), adult Tcell leukemia/lymphoma (ATLL), among others. After accrual of 28 pts, the protocol was amended to allow enrollment of 20 additional pts with CD30+ non-ALCL PTCL (with ALCL allowed in Canada). Pts could receive prephase steroids and/or 1 cycle of CHOPequivalent chemotherapy prior to study entry. 6 pts were treated in a safety lead-in cohort and all pts received CHEP-BV at the recommended phase 2 dose: 6 x 21-day cycles of CHP+BV (1.8mg/kg) on d1 and etoposide 100mg/m2 on d1-3. G-CSF prophylaxis was mandatory. Pts in response after CHEP-BV could receive BV consolidation (1.8mg/kg q3w) for up to 10 additional cycles (16 total BV cycles) either after ASCT or CHEP-BV if no ASCT was performed. The co-primary endpoints were safety and the CR rate (Deauville score 1-3) by PET-CT after CHEP-BV assessed by investigators according to the 2014 Lugano classification. Secondary endpoints were PFS and OS. Results: Accrual has completed and 48 pts were enrolled;all were evaluable for toxicity, 46 were evaluable for efficacy. 16 pts had ALCL (13 ALK+, 3 ALK-) and 32 had non-ALCL PTCL subtypes, including 18 with AITL, 11 with PTCL NOS, 2 with T-follicular helper PTCL, and 1 with ATLL. Baseline characteristics are shown in Table. 43 pts completed CHEP-BV, 2 had progressive disease (PD) prior to completion, 1 pt discontinued CHEP-BV early (MD discretion), 1 pt died due to COVID-19, and 1 remains on CHEP-BV. Of 43 pts who completed CHEP-BV, 24 proceeded to ASCT and 19 did not. 33 (74%) pts received BV consolidation (20 after ASCT, 13 directly after CHEP-BV) and completed a median 8 of the planned 10 cycles (range, 1-10). 13 pts completed all cycles of consolidation;19 pts discontinued early-12 due to adverse events (AE), 5 due to PD, and 2 due to patient/physician choice. The most frequent CHEP-BV related AEs (all grades, G) include fatigue (73%), peripheral sensory neuropathy (67%), anemia (62.5%), nausea (56%), neutropenia (50%), lymphopenia (44%), leukopenia (42%), thrombocytopenia (40%), elevated transaminases (33%). The most common G3+ AEs were neutropenia (37.5%), febrile neutropenia (23%), lymphopenia (21%), anemia (19%), thrombocytopenia (19%). There were 5 deaths, 4 due to PD and 1 due to COVID-19 infection during C3 of CHEP-BV. The interim (n=46) ORR and CR rates (after 3 CHEP-BV cycles, except 1 pt after 2) were 96% and 59% (27 CR, 17 PR), respectively. At completion of CHEP-BV (n=46), the ORR was 91% with 80% CR (37 CR, 5 PR, 4 PD). The ORR/CR rates in ALCL (n=16) vs non-ALCL (n=30) pts were 94%/94% vs 90%/73%, respectively. The ORR/CR rates in pts with CD30 expression 1-9% (n=15) vs 10+% (n=31) were 93%/67% and 90%/87%, respectively. The median follow-up in surviving pts is 1 .1 months (range, 0.9-32.5). The overall 18mo PFS and OS were 61% and 89%;18mo PFS by subgroup: ALCL 81%, non-ALCL 49%, CD30 1-9% 48%, CD30 10+% 67%. Landmark 1y PFS from end of CHEP-BV in responding pts (n=41) was 82% in pts who underwent ASCT vs 48% in pts who did not Conclusions: In a cohort of pts with mostly non-ALCL CD30-expressing PTCL, CHEP-BV (+/-ASCT) followed by BV consolidation was tolerable and effective.

16.
27th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD) ; : 4125-4126, 2021.
Article in English | Web of Science | ID: covidwho-1736114

ABSTRACT

Humanitarian challenges, including natural disasters, food insecurity, climate change, racial and gender violence, environmental crises, the COVID-19 coronavirus pandemic, human rights violations, and forced displacements, disproportionately impact vulnerable communities worldwide. According to UN OCHA, 235 million people will require humanitarian assistance in 2021(1). Despite these growing perils, there remains a notable paucity of data science research to scientifically inform equitable public policy decisions for improving the livelihood of at-risk populations. Scattered data science efforts exist to address these challenges, but they remain isolated from practice and prone to algorithmic harms concerning lack of privacy, fairness, interpretability, accountability, transparency, and ethics. Biases in data-driven methods carry the risk of amplifying inequalities in high-stakes policy decisions that impact the livelihood of millions of people. Consequently, proclaimed benefits of data-driven innovations remain inaccessible to policymakers, practitioners, and marginalized communities at the core of humanitarian actions and global development. To help fill this gap, we propose the Data-driven Humanitarian Mapping Research Program, which focuses on developing novel data science methodologies that harness human-machine intelligence for high-stakes public policy and resilience planning.

18.
Journal of Stem Cells ; 16(2-3):73-90, 2021.
Article in English | Scopus | ID: covidwho-1481599

ABSTRACT

Stem cell therapy is widely used for the treatment of disorders of the blood and immune system but there is comparatively less research devoted to its efficacy in infectious diseases. Although several antibiotics and antivirals have been discovered for the treatment of infectious diseases, a new challenge is posed to the researchers due to the emergence of multiple drug resistance in infectious agents. Infectious agents like SARS COV-2, Mtb (Mycobacterium tuberculosis), HIV and Hepatitis can cause severe tissue and organ damage which can be irreparable. Stem cells, owing to their ability to pervade into the injured region, regenerate and modulate the immune function, can be used as a method to reverse this damage. With the dramatic increase in the number of cases caused by the COVID-19 pandemic, it has become crucial to manage the most severe symptoms such as Acute Respiratory Distress Syndrome (ARDS) and sepsis which have shown promising improvement with the administration of Mesenchymal Stem cells (MSCs) in ongoing clinical trials. This review discusses the scope of stem cell therapy to control some of the most fatal symptoms observed in various infectious diseases. © 2021 Nova Science Publishers, Inc.

19.
Chest ; 160(4):A556-A557, 2021.
Article in English | EMBASE | ID: covidwho-1458383

ABSTRACT

TOPIC: Chest Infections TYPE: Original Investigations PURPOSE: Viral Respiratory illnesses such as Covid-19 and Influenza pose significant health challenges worldwide. There are more than 150M confirmed cases of Covid-19 with a reported 3.15M deaths (as of April, 2021). The WHO reports there to be ~ 1 billion influenza cases and 290-650K influenza-associated deaths annually. A signature feature of these illnesses is an early infection period that, if insufficiently recognized and controlled early, can lead to viral spread and avoidable morbidity/mortality. The need for personalized, remote care tools that facilitate early detection and triage of viral illness has never been greater. To address this gap, we developed an institutional software, Vironix, that uses machine-learned (ML) prediction models to enable real-time risk stratification and decision support for global organizations. METHODS: ML models were trained on clinical characteristic data from East and South Asia, Western Europe, and USA. Algorithms take an input of symptom, profile, biometric, and exposure data and return an assessment of disease severity. Covid-19 algorithms were validated on computer generated patient vigenttes and deployed in the Vironix web app among 22 participants in a small business commercial pilot for member self-screening. Members conducted daily health assessments and received personalized decision support while organization managers received work-from-home recommendations and compliant symptom monitoring without seeing member health data. For influenza, Vironix ML algorithms were tested on a dataset (with a 90/10 train test split) collected from one academic and two community emergency rooms from March 2014 to July 2017 (Hong et al.). RESULTS: ML-predictions showed 87.6% accuracy, 85.5% sensitivity, and 87.8% specificity in identifying severe Covid-19 presentations in an out-of-sample validation set of 5,000 patient cases. After 4-months pilot use, Vironix issued 14 stay-at-home and 10 healthcare escalation recommendations while maintaining 30-day and 7-day user retention of 66% and 72%, greatly exceeding common app adoption rates. ML predictions for the Influenza data set showed 67.8% accuracy, 71.7% sensitivity, and 65.4% specificity in identifying admissible or dischargeable presentations of influenza in an out-of-sample validation set of 56,000 patient cases. CONCLUSIONS: Covid-19 ML-severity assessments showed strong accuracy, sensitivity, and specificity in identifying severe clinical presentations. The deployed web-app showed high adoption with members receiving relevant decision support. Flu algorithm performance could be bolstered by inclusion of biometric features. Additional controlled trials could be conducted to establish validated markers of health improvement and early illness detection resulting from Vironix use. The overall methodology for mapping clinical characteristic data into patient scenarios for training ML classifiers of health deterioration is generalizable for a variety of potential software and hardware deployments across disease spaces. CLINICAL IMPLICATIONS: The technology detailed in this study represents a potential low cost, scalable, hardware/software agnostic, global solution for early detection and intervention on infectious respiratory illness. These solutions can be integrated into remote care and institutional wellness workflows to support public health initiatives. DISCLOSURES: No relevant relationships by Anna Berryman, source=Web Response No relevant relationships by Shreyas Iyer, source=Web Response No relevant relationships by Vinay Konda, source=Web Response Advisory Committee Member relationship with ABMRCC Please note: $1-$1000 by Chris Landon, source=Web Response, value=Consulting fee Removed 04/28/2021 by Chris Landon, source=Web Response Consultant relationship with ABM Respiratory Please note: 11/20 - date Added 04/30/2021 by Chris Landon, source=Web Response, value=Consulting fee no disclosure on file for Nicholas Mark;No relevant relationships by James Morrill, source=Web R sponse No relevant relationships by Sriram Ramanathan, source=Web Response Owner/Founder relationship with Vironix Health, Inc Please note: 05/2020 - Present Added 04/28/2021 by Sumanth Swaminathan, source=Web Response, value=Ownership interest Owner/Founder relationship with Vironix Health Please note: 04/2020-Now Added 05/10/2021 by Botros Toro, source=Web Response, value=Ownership interest Consultant relationship with Vironix Please note: 2019-present Added 04/28/2021 by Nicholas Wysham, source=Web Response, value=Ownership interest

20.
American Journal of Respiratory and Critical Care Medicine ; 203(9):2, 2021.
Article in English | Web of Science | ID: covidwho-1407579
SELECTION OF CITATIONS
SEARCH DETAIL